Laden…
N-(1-adamantyl)-1-(5-fluoropentyl)indazole-3-carboxamide
N-(1-adamantyl)-1-(5-fluoropentyl)indazole-3-carboxamide (5F-AKB48) is a synthetic cannabinoid that acts as a potent agonist at the CB1 and CB2 receptors. It was developed as a designer drug and is known for its strong psychoactive effects, which can be associated with significant health risks.
Translation in progress
The German version has more complete content. This English page is being expanded; safety-critical risk and interaction sections may still appear while translation continues.
Receptor Targets
Mechanism of Action
Designations
IUPAC: N-(1-adamantyl)-1-(5-fluoropentyl)indazole-3-carboxamide
Receptor Profile
Der CB1-Rezeptor ist ein Gi/Go-gekoppelter Cannabinoidrezeptor, der vorwiegend im zentralen Nervensystem exprimiert wird. Er moduliert Neurotransmitterfreisetzung und ist Teil des Endocannabinoidsystems.
Der CB2-Rezeptor ist ein Gi-gekoppelter Cannabinoidrezeptor, der hauptsächlich auf Immunzellen und in geringerem Maße im ZNS exprimiert wird. Er moduliert Entzündungsprozesse und Immunantworten.
Synapedia Evidence
Effects & Pharmacology is partially translated. Some details are still being expanded.
5F-AKB48 functions primarily as an agonist at the cannabinoid receptors CB1 and CB2, leading to its psychoactive effects.
Known Effects
Individual effects may vary significantly. These are pharmacologically documented effects.
Risks & Harm Reduction translation in progress
English prose is being expanded. Safety-critical structured data may still be shown when available.
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.